Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBeijing Friendship Hospital
About this trial
EBV-HLH is a rare disease with high mortality, especially for those with intestinal involvement. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.
Eligibility criteria
Qualifiers
Met HLH-2004 diagnostic criteria;
EBV-DNA in the peripheral blood > 1000 copies/ml or EBV-encoded small RNA (EBER) detected in tissues;
Imaging revealed severe intestinal lesions and biopsy confirmed EBV-encoded small RNA (EBER) in the tissues;
Age >18 years old, gender is not limited;
Disqualifiers
Active infections (viral, bacterial, fungal or parasitic);
Diagosed with malignant tumos within 5 years；
Uncontrolled symptoms or other diseases including, but not limited to, unstable angina pectoris, arrhythmia, respiratory failure, severe hepatic or renal insufficiency, severe coagulation dysfunction, mental illness, or other conditions deemed by the attending physician to be contraindications to surgery;
Heart function above grade II (NYHA);
Trial design
Treatments tested in this trial
- Segmental bowel resection combined with the DEP regimen
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov